tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market
Advertisement

Alnylam Pharma (ALNY) Stock Forecast & Price Target

Compare
1,297 Followers
See the Price Targets and Ratings of:

ALNY Analyst Ratings

Strong Buy
28Ratings
Strong Buy
22 Buy
6 Hold
0 Sell
Based on 28 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$440.60
▼(-3.03% Downside)
Based on 28 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $440.60 with a high forecast of $570.00 and a low forecast of $290.00. The average price target represents a -3.03% change from the last price of $454.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"234":"$234","571":"$571","318.25":"$318.3","402.5":"$402.5","486.75":"$486.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":570,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$570.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":440.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$440.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":290,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$290.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[234,318.25,402.5,486.75,571],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.8,414.73846153846154,427.67692307692306,440.61538461538464,453.55384615384617,466.4923076923077,479.4307692307692,492.36923076923074,505.3076923076923,518.2461538461539,531.1846153846154,544.123076923077,557.0615384615385,{"y":570,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.8,404.7846153846154,407.7692307692308,410.75384615384615,413.73846153846154,416.7230769230769,419.70769230769235,422.69230769230774,425.6769230769231,428.6615384615385,431.6461538461539,434.63076923076926,437.61538461538464,{"y":440.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.8,393.2,384.6,376,367.4,358.8,350.2,341.6,333,324.4,315.8,307.2,298.6,{"y":290,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":268.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$570.00Average Price Target$440.60Lowest Price Target$290.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on ALNY
Truist Financial
Truist Financial
Buy
Reiterated
08/15/25
Alnylam Pharma (ALNY) Gets a Buy from Truist Financial
Stifel Nicolaus Analyst forecast on ALNY
Stifel Nicolaus
Stifel Nicolaus
$441
Buy
-2.94%
Downside
Reiterated
08/14/25
Stifel Nicolaus Remains a Buy on Alnylam Pharma (ALNY)Stifel analyst Paul Matteis reiterated a Buy rating and $441.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
H.C. Wainwright Analyst forecast on ALNY
H.C. Wainwright
H.C. Wainwright
$500$570
Buy
25.45%
Upside
Reiterated
08/07/25
Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating
TD Cowen Analyst forecast on ALNY
TD Cowen
TD Cowen
$482
Buy
6.08%
Upside
Reiterated
08/06/25
TD Cowen Remains a Buy on Alnylam Pharma (ALNY)
J.P. Morgan Analyst forecast on ALNY
J.P. Morgan
J.P. Morgan
$348$475
Buy
4.54%
Upside
Reiterated
08/06/25
Alnylam Pharma: Strong Growth Prospects and Transition to Profitability Support Buy Rating
Leerink Partners Analyst forecast on ALNY
Leerink Partners
Leerink Partners
$246$343
Hold
-24.51%
Downside
Reiterated
08/06/25
Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners
Wolfe Research Analyst forecast on ALNY
Wolfe Research
Wolfe Research
Hold
Upgraded
08/04/25
Alnylam upgraded to Peer Perform from Underperform at Wolfe ResearchAlnylam upgraded to Peer Perform from Underperform at Wolfe Research
Oppenheimer Analyst forecast on ALNY
Oppenheimer
Oppenheimer
$490
Buy
7.84%
Upside
Upgraded
08/04/25
Alnylam upgraded to Outperform from Perform at OppenheimerAlnylam upgraded to Outperform from Perform at Oppenheimer
UBS
$403$550
Buy
21.04%
Upside
Reiterated
08/04/25
Alnylam price target raised to $550 from $403 at UBSAlnylam price target raised to $550 from $403 at UBS
Canaccord Genuity Analyst forecast on ALNY
Canaccord Genuity
Canaccord Genuity
$390$415
Buy
-8.67%
Downside
Reiterated
08/01/25
Alnylam price target raised to $415 from $390 at CanaccordAlnylam price target raised to $415 from $390 at Canaccord
Raymond James Analyst forecast on ALNY
Raymond James
Raymond James
$308$424
Buy
-6.69%
Downside
Initiated
08/01/25
Alnylam assumed with an Outperform at Raymond JamesAlnylam assumed with an Outperform at Raymond James
Scotiabank Analyst forecast on ALNY
Scotiabank
Scotiabank
$342$450
Buy
-0.96%
Downside
Reiterated
08/01/25
Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Wells Fargo Analyst forecast on ALNY
Wells Fargo
Wells Fargo
$333$395
Hold
-13.07%
Downside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Baxter International (NYSE: BAX)
Barclays Analyst forecast on ALNY
Barclays
Barclays
$329$460
Buy
1.24%
Upside
Reiterated
08/01/25
Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on ALNY
Piper Sandler
Piper Sandler
$304$449
Buy
-1.18%
Downside
Reiterated
08/01/25
Piper Sandler Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on ALNY
Truist Financial
Truist Financial
Buy
Reiterated
08/15/25
Alnylam Pharma (ALNY) Gets a Buy from Truist Financial
Stifel Nicolaus Analyst forecast on ALNY
Stifel Nicolaus
Stifel Nicolaus
$441
Buy
-2.94%
Downside
Reiterated
08/14/25
Stifel Nicolaus Remains a Buy on Alnylam Pharma (ALNY)Stifel analyst Paul Matteis reiterated a Buy rating and $441.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).
H.C. Wainwright Analyst forecast on ALNY
H.C. Wainwright
H.C. Wainwright
$500$570
Buy
25.45%
Upside
Reiterated
08/07/25
Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating
TD Cowen Analyst forecast on ALNY
TD Cowen
TD Cowen
$482
Buy
6.08%
Upside
Reiterated
08/06/25
TD Cowen Remains a Buy on Alnylam Pharma (ALNY)
J.P. Morgan Analyst forecast on ALNY
J.P. Morgan
J.P. Morgan
$348$475
Buy
4.54%
Upside
Reiterated
08/06/25
Alnylam Pharma: Strong Growth Prospects and Transition to Profitability Support Buy Rating
Leerink Partners Analyst forecast on ALNY
Leerink Partners
Leerink Partners
$246$343
Hold
-24.51%
Downside
Reiterated
08/06/25
Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners
Wolfe Research Analyst forecast on ALNY
Wolfe Research
Wolfe Research
Hold
Upgraded
08/04/25
Alnylam upgraded to Peer Perform from Underperform at Wolfe ResearchAlnylam upgraded to Peer Perform from Underperform at Wolfe Research
Oppenheimer Analyst forecast on ALNY
Oppenheimer
Oppenheimer
$490
Buy
7.84%
Upside
Upgraded
08/04/25
Alnylam upgraded to Outperform from Perform at OppenheimerAlnylam upgraded to Outperform from Perform at Oppenheimer
UBS
$403$550
Buy
21.04%
Upside
Reiterated
08/04/25
Alnylam price target raised to $550 from $403 at UBSAlnylam price target raised to $550 from $403 at UBS
Canaccord Genuity Analyst forecast on ALNY
Canaccord Genuity
Canaccord Genuity
$390$415
Buy
-8.67%
Downside
Reiterated
08/01/25
Alnylam price target raised to $415 from $390 at CanaccordAlnylam price target raised to $415 from $390 at Canaccord
Raymond James Analyst forecast on ALNY
Raymond James
Raymond James
$308$424
Buy
-6.69%
Downside
Initiated
08/01/25
Alnylam assumed with an Outperform at Raymond JamesAlnylam assumed with an Outperform at Raymond James
Scotiabank Analyst forecast on ALNY
Scotiabank
Scotiabank
$342$450
Buy
-0.96%
Downside
Reiterated
08/01/25
Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Wells Fargo Analyst forecast on ALNY
Wells Fargo
Wells Fargo
$333$395
Hold
-13.07%
Downside
Reiterated
08/01/25
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Baxter International (NYSE: BAX)
Barclays Analyst forecast on ALNY
Barclays
Barclays
$329$460
Buy
1.24%
Upside
Reiterated
08/01/25
Barclays Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Piper Sandler Analyst forecast on ALNY
Piper Sandler
Piper Sandler
$304$449
Buy
-1.18%
Downside
Reiterated
08/01/25
Piper Sandler Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

1 Month
xxx
Success Rate
16/27 ratings generated profit
59%
Average Return
+1.23%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.23% per trade.
3 Months
xxx
Success Rate
21/30 ratings generated profit
70%
Average Return
+12.00%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +12.00% per trade.
1 Year
Kostas BiliourisBMO Capital
Success Rate
20/22 ratings generated profit
91%
Average Return
+42.78%
reiterated a buy rating 25 days ago
Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +42.78% per trade.
2 Years
xxx
Success Rate
22/22 ratings generated profit
100%
Average Return
+99.31%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +99.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
9
6
5
3
1
Buy
48
51
35
41
37
Hold
22
19
15
13
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
79
76
55
57
53
In the current month, ALNY has received 38 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 440.60.
Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is $0.27 with a range of -$1.10 to $2.24. The previous quarter’s EPS was -$0.51. ALNY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.49% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.
Next quarter’s earnings estimate for ALNY is $0.27 with a range of -$1.10 to $2.24. The previous quarter’s EPS was -$0.51. ALNY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 33.49% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $919.13M with a range of $654.00M to $1.14B. The previous quarter’s sales results were $773.69M. ALNY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 43.05% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.
Next quarter’s sales forecast for ALNY is $919.13M with a range of $654.00M to $1.14B. The previous quarter’s sales results were $773.69M. ALNY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 43.05% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 440.60.
    What is ALNY’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for ALNY, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is ALNY a Buy, Sell or Hold?
        Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 22 buy ratings, 6 hold ratings and 0 sell ratings.
          What is Alnylam Pharmaceuticals’s price target?
          The average price target for Alnylam Pharmaceuticals is 440.60. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $570.00 ,the lowest forecast is $290.00. The average price target represents -3.03% Decrease from the current price of $454.38.
            What do analysts say about Alnylam Pharmaceuticals?
            Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 28 Wall Streets Analysts.
              How can I buy shares of ALNY?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis